Skip to main content

Trigger Point Pain, Myofascial

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Young BioPharma
Young BioPharmaMA - Lowell
1 program
Positional release therapyN/A1 trial
Active Trials
NCT04765891Completed60Est. Feb 2018
MTI
MTIUT - Salt Lake City
1 program
extracorporeal shock wave and conventional treamentN/A1 trial
Active Trials
NCT04778462Completed60Est. Apr 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MTIextracorporeal shock wave and conventional treament
Young BioPharmaPositional release therapy

Clinical Trials (2)

Total enrollment: 120 patients across 2 trials

NCT04778462MTIextracorporeal shock wave and conventional treament

Myoelectric Activity of Upper Trapezius Trigger Point

Start: Feb 2020Est. completion: Apr 202160 patients
N/ACompleted
NCT04765891Young BioPharmaPositional release therapy

Positional Release Therapy and Therapeutic Massage Reduce Muscle Trigger and Tender Points

Start: Dec 2017Est. completion: Feb 201860 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.